Muhammad Arham | AI in Drug Discovery | Innovative Research Award

Published on by Computational Biologists

Innovative Research Award

Muhammad Arham
The University of Faisalabad, Pakistan

Muhammad Arham
Affiliation The University of Faisalabad
Country Pakistan
Google Scholar tRiYSVcAAAAJ&hl
Documents 6
Citations 5
h-index 2
Subject Area AI in Drug Discovery
Event Computational Biologists Awards
ORCID 0009-0008-8496-9615

Muhammad Arham is a researcher affiliated with The University of Faisalabad whose recorded research profile is associated with artificial intelligence applications in drug discovery. Available bibliographic information identifies a Scopus author record containing two documents, two citations, and an h-index of 1. These indicators provide a limited quantitative snapshot of scholarly activity and should be interpreted in relation to publication age, field norms, and research development. [1]

Abstract

Muhammad Arham is affiliated with The University of Faisalabad, Pakistan, and has a documented research profile connected with artificial intelligence in drug discovery. His indexed record currently reports two documents, two citations, and an h-index of 1. The research area represents an interdisciplinary intersection of computational biology, artificial intelligence, pharmaceutical science, and data-driven discovery. Such approaches can support the analysis of biological and chemical information, prioritization of candidate compounds, prediction of molecular properties, and development of computational workflows for drug research. The present profile summarizes available scholarly indicators and assesses relevance to an Innovative Research Award within computational biology. [1]

Keywords

Artificial intelligence; drug discovery; computational biology; bioinformatics; machine learning; pharmaceutical research; molecular modeling; computational drug design. These keywords describe the interdisciplinary context in which artificial intelligence methods may be applied to biological and pharmaceutical research problems.

Introduction

Artificial intelligence has become an important computational approach in modern drug discovery, where large biological, chemical, and clinical datasets can be analyzed using machine learning and related computational techniques. AI-assisted workflows may contribute to target identification, compound screening, molecular property prediction, and optimization of candidate molecules. [2] Within computational biology, these methods provide a bridge between biological data interpretation and predictive computational modeling.

Research Profile

The available profile places Muhammad Arham within an interdisciplinary research environment at The University of Faisalabad, with AI in Drug Discovery identified as the principal subject area. The Scopus record associated with author ID 60694808200 contains two indexed documents and two citations, with an h-index of 1. These records establish an emerging scholarly profile, although bibliometric indicators alone cannot fully characterize methodological quality or scientific contribution. [1]

Research Contributions

Research at the intersection of artificial intelligence and drug discovery can contribute computational methods for handling complex molecular and biological datasets. Relevant approaches include machine learning models, predictive analytics, molecular representation, virtual screening, and computational prioritization of drug candidates. [2] The documented subject area therefore aligns with a broader research direction in which computational techniques are used to support pharmaceutical discovery and biological interpretation.

Publications

The available Scopus record reports two documents associated with the researcher. Because the supplied information does not provide publication titles, journals, publication years, authorship positions, or article-level DOI information, no additional publication details are inferred here. The reported document count should therefore be regarded as the bibliographic information available for this profile at the time of assessment. [1]

Research Impact

The recorded profile currently has two citations and an h-index of 1. These indicators suggest measurable but early-stage bibliometric visibility. Citation counts and h-index values can vary substantially according to discipline, publication age, database coverage, and citation practices, so they are best considered alongside qualitative evidence such as methodological originality, reproducibility, collaboration, and practical relevance. [1]

Award Suitability

The research area identified for Muhammad Arham is relevant to an Innovative Research Award because AI-driven drug discovery is a developing interdisciplinary field with applications across computational biology and pharmaceutical research. The available evidence establishes subject-area relevance and a documented scholarly record, while the limited bibliometric volume indicates that award evaluation should also consider the specific novelty, technical rigor, validation, and potential significance of the underlying research contributions. [2] Final award determination should therefore be based on the complete nomination dossier and independent assessment criteria.

Conclusion

Muhammad Arham’s documented academic profile reflects an emerging research trajectory associated with AI in Drug Discovery at The University of Faisalabad. The available bibliometric record includes two documents, two citations, and an h-index of 1. While these metrics provide a concise indication of indexed scholarly activity, they do not independently establish research quality or innovation. The profile is nevertheless thematically aligned with computational approaches to contemporary drug discovery and may be considered within an award assessment framework that evaluates substantive scientific contribution. [1]

References

  1. Journal article. (2026). Harnessing Deep Learning Models for Guide RNA Optimization and Off-Target Prediction in CRISPR Systems.
    https://doi.org/10.1002/biot.70255
  2. Google Scholar. (n.d.). Rahim Zahedi, Author ID tRiYSVcAAAAJ&hl. Google Scholar author profile.
    https://scholar.google.com/citations?user=tRiYSVcAAAAJ&hl=en
  3. Journal article. (2026). Next-Generation Artificial Intelligence Strategies for Mechanistic Cancer Target Discovery and Drug Development: A State-of-the-Art Review.
    https://doi.org/10.1016/j.drudis.2018.11.014
  4. ORCID. (n.d.). ORCID record: Muhammad Arham. ORCID.
    https://orcid.org/0009-0008-8496-9615
  5. Computational Biologists Awards. (2026.). Official award website.
    https://computationalbiologists.com/

Hua Zhu | AI in Drug Discovery | Best Researcher Award

Published on by Computational Biologists

Prof. Hua Zhu | AI in Drug Discovery | Best Researcher Award   

Researcher, Ph.D. Supervisor at  Beijing Cancer Hospital & Institute, Peking University, China.
Prof. Hua Zhu is a distinguished researcher and full professor at the Department of Nuclear Medicine, Beijing Cancer Hospital & Institute, Peking University. With a focused career in molecular imaging and nuclear medicine, Prof. Zhu has made pioneering contributions to the clinical translation of cancer theranostics. His extensive work in radiopharmaceuticals, multimodality molecular probes, and targeted delivery systems places him among the leading scientists in his field.

🎓 Academic Background:

Prof. Zhu earned his Bachelor of Science degree in Applied Chemistry from Nanjing Normal University in 2006, followed by a Ph.D. in Inorganic Chemistry (specializing in Radiopharmaceuticals) from the Shanghai Institute of Applied Physics, Chinese Academy of Sciences in 2011. He also enriched his academic perspective through a visiting assistant professorship at Stanford University from 2014 to 2015.

Profile:

Professional Experience:

Prof. Hua Zhu is a full professor at the Department of Nuclear Medicine, Beijing Cancer Hospital & Institute, Peking University. He has over a decade of professional experience in the development of molecular imaging agents and targeted radiopharmaceuticals for cancer diagnosis and therapy. He has led multiple national-level research projects and previously served as a visiting assistant professor at Stanford University, contributing to international research collaboration. His expertise spans from radionuclide production to clinical translation, and he actively holds leadership roles in key academic societies related to nuclear medicine and imaging science.

🧪 Research Focus:

Prof. Zhu’s research is dedicated to the development of molecular imaging tools and targeted delivery systems for cancer diagnosis and treatment. His focus areas include the production and application of solid-target based radionuclides such as ⁶⁴Cu, ⁸⁹Zr, and ¹²⁴I, and the design of multimodal imaging probes. His efforts are instrumental in bridging the gap between bench research and clinical oncology.

🏆 Academic Honors:

Prof. Zhu has received numerous prestigious honors that recognize his research excellence and leadership in the field:

  • 🌟 National-level Young Talent (2023)

  • 🧠 Young Beijing Scholar (2024)

  • 📘 Boya Young Scholar (2025)

  • 🌆 “Bai Qian Wan” Talent of Beijing (2019)

  • 💫 Beijing Young Top-notch Talent (2018)

  • ✨ Beijing Nova Program (2017)

🔬 Research Leadership:

As a principal investigator, Prof. Zhu leads four National Natural Science Foundation of China (NSFC) projects and over ten national/provincial initiatives. His work exemplifies effective leadership in interdisciplinary and cross-institutional collaboration.

Publications:

  1. Detectability of Al¹⁸F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer
    Clinical Nuclear Medicine, 2025

  2. Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer
    Molecular Pharmaceutics, 2025

  3. Radiolabelled Anti-PD-L1 Peptide PET/CT in Predicting the Efficacy of Neoadjuvant Immunotherapy Combined With Chemotherapy in Resectable Non-Small Cell Lung Cancer
    Annals of Nuclear Medicine, 2025

  4. [¹⁷⁷Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma
    Bioconjugate Chemistry, 2025

  5. A Whole-Body Imaging Technique for Tumor-Specific Diagnostics and Screening of B7H3-Targeted Therapies
    Journal of Clinical Investigation, 2025 (Open Access)

  6. Development and First-in-Human Evaluation of a Site-Specific [¹⁸F]-Labeled PD-L1 Nanobody PET Radiotracer for Noninvasive Imaging in NSCLC
    Bioorganic Chemistry, 2025

  7. Radioiodinated Nanobody ImmunoPET Probe for In Vivo Detection of CD147 in Pan-Cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2025

  8. Strategies for Specific Multimodal Imaging of Cancer-Associated Fibroblasts and Applications in Theranostics of Cancer
    Open Access Review

  9. Efficacy of Radiolabelled PD-L1-Targeted Nanobody in Predicting and Evaluating the Combined Immunotherapy and Chemotherapy for Resectable Non-Small Cell Lung Cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2025

  10. Recent Advances in Emerging Radiopharmaceuticals and the Challenges in Radiochemistry and Analytical Chemistry
    Review Article, 2025

Kazem Karami | AI in Drug Discovery | Best Researcher Award

Published on by Computational Biologists

Prof. Kazem  Karami |  AI in Drug Discovery |  Best Researcher Award

academic-member of chemistry department at  isfahan university of technology , Iran.

Prof. Dr. Kazem Karami, born on March 30, 1966, in Ilam, Iran, is a distinguished Iranian chemist renowned for his extensive contributions to the field of inorganic and organometallic chemistry. He currently serves as a Professor in the Department of Chemistry at Isfahan University of Technology, where he has been shaping the future of chemical science through teaching, mentorship, and cutting-edge research since 2006.

Profile:

🎓 Academic Background:

Dr. Karami holds a Ph.D. in Inorganic Chemistry from Bu-Ali Sina University, where he conducted advanced research under the supervision of Prof. S.J. Sabounchei. His dissertation focused on the synthesis and characterization of keto-stabilized phosphorus ylides and various metal complexes, a theme that would define much of his future work. Prior to this, he earned his M.Sc. from Tehran University of Teacher Training and a B.Sc. from Lorestan University.

🔬 Research Interests:

Prof. Karami’s research encompasses a broad and impactful range of topics, including:

  • Design and synthesis of bioactive organometallic complexes

  • C-H activation and cyclopalladation involving phosphorus ylides

  • Development of orthopalladated complexes for anticancer applications

  • Nanocomposites for environmental remediation and biosensing

  • Advanced studies in coordination chemistry, sol-gel processes, and catalysis

His work has consistently bridged synthetic chemistry with biological and environmental relevance, particularly through interactions of complexes with DNA, BSA, and cancer cell lines.

🏆 Awards & Scientific Leadership:

With a career marked by research excellence and leadership, Prof. Karami has been involved in more than 15 research projects funded by the Iranian National Science Foundation (INSF). Many of his projects focus on anticancer metal complexes, environmental chemistry, and nanostructured materials. He has also served on editorial boards and national research committees, reflecting his status as a thought leader in his field.

Publication:

  1. In Vitro Cytotoxicity Studies of Palladacyclic Complexes Containing the Symmetric Diphosphine Bridging Ligand: Studies of Their Interactions With DNA and BSA

  2. Design and Synthesis of a Novel Trinuclear Palladium(II) Complex Containing an Oxime Chelate Ligand: Determining the Interaction Mechanism With the DNA Groove and BSA Site I

  3. Palladium Nanoparticles Supported on Polymer: An Efficient and Reusable Heterogeneous Catalyst for the Suzuki Cross-Coupling Reactions and Aerobic Oxidation of Alcohols

  4. BSA Nanoparticles as Controlled Release Carriers for Isophthalaldoxime Palladacycle Complex: Synthesis, Characterization, In Vitro Evaluation, Cytotoxicity, and Release

  5. Application of Dimeric Orthopalladate Complex of Homoveratrylamine as an Efficient Catalyst in the Heck Cross-Coupling Reaction

  6. Synthesis and Application of Ortho-Palladated Complex of (4-Phenylbenzoylmethylene) Triphenylphosphorane as a Highly Active Catalyst in the Suzuki Cross-Coupling Reaction

  7. A Novel TMD/MOF Composite for Highly Selective Adsorption of Methylene Blue Dye From Aqueous Mixture of MB and MO

  8. A Novel Nanohybrid Based on MIL-101(Cr)/PANI/Ag for the Adsorption of Cationic Methylene Blue Dye From Aqueous Solution

  9. Synthesis and Characterization of Two New Trans Palladium(II) Complexes Containing Benzylamine Ligand: DNA/BSA Interactions, Molecular Docking, and In Vitro Cytotoxic Activity

  10. An Efficient Palladium Catalytic System for Microwave-Assisted Cyanation of Aryl Halides

  11. Synthesis of a Novel Trinuclear Palladium Complex: The Influence of an Oxime Chelate Ligand on Biological Evaluation Toward Double-Strand DNA, BSA Protein, and Molecular Docking

  12. Bis(Dibenzylidene Acetone) Palladium(0) Catalyst for Glycerol Oxidation in Half Cell and in Alkaline Direct Glycerol Fuel Cell

  13. Synthesis and Spectroscopic Characterization Study of New Palladium Complexes Containing Bioactive O,O-Chelated Ligands: Evaluation of the DNA/Protein BSA Interaction and In Vitro Cytotoxicity

  14. Dinuclear Bridged Biphosphinic and Mononuclear Cyclopalladated Complexes of Benzylamines: Synthesis, Structural Characterization, and Antitumor Activity

  15. Application of Dimeric Orthopalladated Complex in Suzuki–Miyaura Cross-Coupling Reaction Under Microwave Irradiation and Conventional Heating

  16. An Investigation on MIL-101(Fe)/PANI/Pd Nanohybrid as a Novel Photocatalyst Based on MIL-101(Fe) MOF for Removing Methylene Blue Dye

  17. Cyclopalladated Complexes of 2-Phenylaniline and Their Catalytic Activity in Suzuki and Heck Reactions Under Mild Conditions

  18. Synthesis, Characterization, and Molecular Docking of New C,N-Palladacycles Containing Pyridinium-Derived Ligands: DNA and BSA Interaction Studies

  19. Polyethylene Glycol-Supported Recyclable NC Palladacycle Catalyst for Heck Cross-Coupling Reactions

  20. Synthesis, Spectroscopic Characterization, and In Vitro Cytotoxicities of New Organometallic Palladium Complexes With Biologically Active β-Diketones: Biological Evaluation and Docking Studies